Ionis Shares Collapse After Phase 3 CARDIO-TTRansform Misses Primary Endpoint
Ionis Pharmaceuticals tumbled in pre-market trading after announcing that the Phase 3 CARDIO-TTRansform study of eplontersen failed to meet its primary efficacy endpoint - a composite of cardiovascular death and recurrent cardiovascular events through Week 140 versus placebo. The large trial enrolled 1,432 patients at 130 sites across 20 countries.…